Overview
The ISBT 128 labeling standard has received endorsements and support from various international organizations. In this section you will have an opportunity read the positive feedback ICCBBA has received.
Endorsements
Blood Endorsements
European Blood Alliance
Statement of the European Blood Alliance position on the labelling, coding and identification of blood, blood components, tissues and cells
At the Board Meeting in Valletta, Malta, the EBA Board has voted to support the universal use of the ISBT 128 for labelling, coding and
identification of blood, blood components, tissues and cells.
EBA Position Paper on Coding and Labeling - PDF Oct 1, 2010
United Kingdom National Health Service
The United Kingdom National Health Service has published two articles regarding ICCBBA and ISBT 128 labeling in their latest online issue of NHS Blood and Transplant Matters. The articles can be found on page 13 and 14.
08 June 2010
Cellular Therapy Endorsements
WMDA Position Paper Status
The World Marrow Donor Association (WMDA) has posted a position paper discussing how to handle facility confidentiality when labeling Cellular Therapy products from unrelated donors
In this paper the, "WMDA encourages the efforts to adapt ISBT 128 as an effective bar-coded information coding system that supports a globally unique identity,standardized product coding and full traceability of cellular therapy products."
See the position paper here:
WMDA Position Paper - PDF
12 August 2011
WBMT letter to the European Commission Supporting ISBT 128 for Cellular Therapy
The World Network for Blood and Marrow Transplantation” has submitted a letter to the European Commission (EC) supporting ISBT 128 for Cellular Therapy products and recommending that the EC provide a clear indication that the implementation of ISBT 128 for cellular therapy products will be compatible with the European Coding System
See the WBMT letter to the European Commission here: http://www.wbmt.org/
12 August 2011
CTCLAG Joint Statement
The Boards of AABB, ASBMT, ASFA, EBMT, FACT, ICCBBA, ISBT, ISCT, JACIE, NMDP and WMDA issued a consensus statement in support of the use of ISBT 128 in the coding of hematopoietic progenitor cell and other therapeutic cell products.
The Boards of the above organizations encourage cell therapy facilities to move forward with the implementation of ISBT 128 coding and labeling.
Joint Statement - PDF
21 March 2011